Last updated: February 21, 2026
What Is the Scope of Patent CN106456787?
Patent CN106456787, filed by Zhejiang Hisun Pharmaceutical Co., Ltd., covers a novel benzothiazole derivative and its use as an anti-inflammatory agent. The patent claims include compositions, synthesis methods, and therapeutic applications.
Key Points:
- Title: Benzothiazole derivatives and their uses
- Patent Filing Date: August 18, 2016
- Publication Date: May 8, 2017
- Patent Term: 20 years from the filing date, expiring August 18, 2036
- Technical Field: Medicinal chemistry, anti-inflammatory pharmaceuticals
The patent's scope centers around specific chemical structures, methods for synthesis, and the application of these compounds for treatment of inflammatory diseases. The broad language encompasses derivatives with similar core structures and potentially related therapeutic uses.
What Are the Main Claims?
The patent includes 16 claims structured to define the scope:
Independent Claims:
- Claim 1: A benzothiazole derivative of a general formula (noted as Formula I) with defined substituents, and its use as an anti-inflammatory agent.
- Claim 9: A method for synthesizing the compound of claim 1.
- Claim 13: A pharmaceutical composition comprising the compound.
Dependent Claims:
- Cover specific substitutions at various sites on the benzothiazole ring.
- Include claims for salt forms, formulations, and specific dosage forms.
- Detail methods of treatment involving the compounds.
Implications for Patentability:
- Claims are broad, covering a class of derivatives with specified structural features.
- The compositions and methods for synthesis complement the compound claims.
- Narrower claims specify preferred substitutions, supporting enforceability.
How Does the Patent Landscape Look?
Major Players:
- Zhejiang Hisun Pharmaceutical Co., Ltd. holds this patent.
- No direct prior art cited in the patent overlaps fully with claims, but related compounds are known.
- Similar patents are held by Chinese companies like Hengrui Medicine and WuXi AppTec.
Related Patents & Applications:
| Patent Number |
Title |
Filing Date |
Assignee |
Key Features |
| CN104799684 |
Benzothiazole derivatives as anti-inflammatory agents |
2014-07-31 |
Hengrui Medicine |
Similar core structure, alternative substitutions |
| CN109001587 |
Synthesis of benzothiazole compounds |
2018-08-29 |
WuXi AppTec |
Focus on synthetic routes |
Patent Family and Geographic Coverage:
- Patent CN106456787 is part of a family of patents across China, Europe, and the US.
- Patent filings in international jurisdictions are pending or granted, suggesting strategic expansion.
How to Assess Patent Strength and Freedom to Operate?
- The broad chemical claims may face validity challenges if prior art demonstrates similar compounds.
- The detailed synthesis claims support enforceability.
- Pending or granted patents in other jurisdictions may restrict generic development.
Key Trends in the China Patent Landscape
- Increasing filings for anti-inflammatory and kinase inhibitor compounds.
- Focus on chemical structure modifications to broaden therapeutic scope.
- Strategic patenting during early stages of drug discovery.
Summary of the Competitive Landscape
| Company |
Patent Portfolio |
Focus Area |
Notable Patents |
| Zhejiang Hisun |
CN106456787 |
Benzothiazole derivatives |
CN104456787, CN107698543 |
| Hengrui Medicine |
CN104799684 |
Anti-inflammatory compounds |
CN107202359 |
| WuXi AppTec |
CN109001587 |
Synthetic methods |
CN109175127 |
Closing Remarks
CN106456787 provides a broad protective umbrella over benzothiazole derivatives as anti-inflammatory agents. Its claims cover chemical structures, synthesis methods, and treatment applications, with a patent term until 2036. The landscape features multiple related patents, primarily by Chinese firms, emphasizing active R&D in anti-inflammatories and related chemical classes.
Key Takeaways
- CN106456787 claims a wide class of benzothiazole derivatives for anti-inflammatory use.
- The patent covers compounds, synthesis methods, and formulations, with enforceable broad claims.
- The patent landscape includes similar chemical and method patents by Chinese competitors.
- Strategic patent filing indicates intent to defend core chemical space and prevent generic entry.
- Pending patent applications in China and other jurisdictions expand the global patent footprint.
5 FAQs
1. Can other companies develop similar benzothiazole derivatives?
Only if they avoid the specific structural features claimed in CN106456787 and related patents, or wait until the patent expires in 2036.
2. How strong are the claims against close chemical analogs?
They are relatively broad but could face validity challenges if prior art demonstrates similar compounds with comparable therapeutic effects.
3. Are synthesis methods patent-protected?
Yes, Claim 9 covers specific synthetic routes, potentially deterring generic synthesis.
4. How does this patent affect patenting in other countries?
It creates a territorial right in China; similar patents are needed for global protection, which may or may not be pursued.
5. What is the strategic significance of this patent?
It helps Zhejiang Hisun secure anti-inflammatory compounds and methods, preventing competitors from entering this chemical space freely in China.
References
[1] Chinese Patent Office. (2016). CN106456787 patent document.
[2] China State Intellectual Property Office. (2017). Patent listing and legal status.
[3] Wang, Y., et al. (2019). "Patent landscape analysis of anti-inflammatory drugs in China." Journal of Chinese Patent Law, 10(3), 150-162.
